Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00226655 · ClinicalTrials.gov registry record · Phase 3
An Open-Labeled, Extended-Use of XERECEPT (hCRF) for Patients in Studies NTI 0302, 0303, or Other Designated Studies
A Phase 3 study, sponsored by Celtic Pharma Development Services.
- Completed
- Registry status
- Phase 3
- Development phase
- 112
- Enrollment target
NCT00226655: Completed Phase 3 study, sponsored by Celtic Pharma Development Services.
NCT00226655 is a Phase 3 study that has completed, run by Celtic Pharma Development Services. The registered enrollment target is 112 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00226655, a Phase 3 study, has completed, sponsored by Celtic Pharma Development Services.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 112 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the long-term safety and tolerability of human corticotropin-releasing factor (hCRF), XERECEPT®, in patients requiring dexamethasone (Decadron) to treat peritumoral brain edema. This open-label, extended-use study is open to all patients who participate in either of the blinded studies, NTI 0302, NTI 0303, or other designated studies, including patients who may have discontinued blinded study medication early but completed the protocol-stipulated follow-up periods.
Primary Outcome
Number of patients reporting adverse events
Interventions
- DRUG hCRF [XERECEPT (corticorelin acetate injection)]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2005-07 |
| Est. Completion | 2009-04 |
| Phase | Phase 3 |
What the finished NCT00226655 record still lists
NCT00226655 is an interventional study that assigns participants to a tested intervention. The registered 112 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 1 intervention - of which hCRF [XERECEPT (corticorelin acetate injection)] is the first listed.
NCT00226655 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00226655 about?
NCT00226655 is a clinical study titled "An Open-Labeled, Extended-Use of XERECEPT (hCRF) for Patients in Studies NTI 0302, 0303, or Other Designated Studies". The purpose of this study is to examine the long-term safety and tolerability of human corticotropin-releasing factor (hCRF), XERECEPT®, in patients requiring dexamethasone (Decadron) to treat peritumoral brain edema. This open-label, extended-use study is open to all patients who participate in eit...
What is the current status of trial NCT00226655?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 112 participants. The study started on 2005-07. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00226655?
The interventions under investigation include: hCRF [XERECEPT (corticorelin acetate injection)] (DRUG).
Who is sponsoring clinical trial NCT00226655?
This trial is sponsored by Celtic Pharma Development Services, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00226655's enrollment target sits among peer trials
112 1652nd of 2000 higher than 346 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04511013 · 112 participants · Phase 2
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- NCT04551560 · 112 participants · NA
Stress and Congestive Heart Failure
- NCT04872166 · 112 participants · Phase 1
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
- NCT05024773 · 112 participants · Phase 3
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia